Specify a stock or a cryptocurrency in the search bar to get a summary
Vincerx Pharma Inc
VINCVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California. Address: 260 Sheridan Avenue, Palo Alto, CA, United States, 94306
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures VINC
Dividend Analytics VINC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History VINC
Stock Valuation VINC
Financials VINC
Results | 2019 | Dynamics |